Jason Raleigh Nunn
Independent DirectorMr. Jason Raleigh Nunn, also known as Jake, AB, MBA, C.F.A., is Director of Pulmocide Ltd from July 2025. Mr. Nunn serves as an Independent Director at Zenas BioPharma, Inc. since May 2024. He is Independent Director at Addex Therapeutics Ltd. He is Director at Zenas BioPharma Limited since 2024. He is Partner at SR One Capital Management, LP from 2024. He was Venture Partner of SR One Capital Management, LP from January 2023 till 2024. He focuses on later-stage private and public biotech investment opportunities. He serves as an Independent Director at Humanetics Corporation and also served as Director from August, 2022 until 2026. He is a Venture Advisor at New Enterprise Associates, Inc. where he was a partner from 2006 to 2018, focusing on later-stage specialty pharmaceuticals, biotechnology and medical device investments and managing a number of NEA's public investments in healthcare. He has experience in the life science industry as an investor, independent director, research analyst and investment banker. Mr. Nunn served as an Independent Non-Executive Director at Hexima Limited since September 1, 2021 until June 2022. He had been a Partner of New Enterprise Associates since joining in June 2006 until 2018, focusing on later-stage specialty pharmaceuticals, biotechnology and medical device investments and managing a number of NEA's public investments in healthcare. Mr. Nunn focuses on later-stage healthcare, later-stage specialty pharmaceuticals, biotechnology, biopharmaceuticals and medical device investments; and manages a number of NEA's public investments in healthcare. He had been Non-Executive Director of Oventus Medical Limited since February 25, 2020 until September 2023. He served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., where he specialized in public, PIPE and mezzanine-stage life sciences investing. He was a Partner and an analyst of MPM BioEquities Fund, L.P. He joined MPM BioEquities Fund Gmbh & Co Kg in January 2001 and served as its Partner. He served as a Healthcare Research Analyst and Portfolio Manager at Franklin Templeton Investments Corp. He served at Franklin Templeton Group and worked in the health care team lead by Mr. Kurt von Emster. He served as a Co-Manager of the Franklin Global Health Care Fund and the Franklin Large Cap Growth Fund. He served as the Specialty Pharmaceutical and Medical Technology Analyst for few years at Franklin. Mr. Nunn served as a Corporate Finance Analyst in the Health Care Group at Alex Brown & Sons Inc., where he has spent few years working on mergers and acquisitions and new securities offerings for biotechnology and medical technology companies. He had been Independent Non-Executive Director at Addex Therapeutics since June 2018. He served as Independent Director of Regulus Therapeutics Inc. since June 2019 until June 25, 2025. He served as an Investment Banker at Alex, Brown & Sons. He served as a Director of TriVascular Technologies, Inc., from 2008 to February 2016. He serves as a Director of TriVascular, Inc. since March 2008. He served as a Non-Employee Director of Dermira Inc. (acquired by Eli Lilly) since May 2011 until February 19, 2020. He served as board observer at Vertiflex, Incorporated (acquired by Boston Scientific). He had been an Independent Non-Executive Director of Trevena, Inc. since July 2013 until November 05, 2024. He served as a Director of Hyperion Therapeutics, Inc., (acquired by Horizon Pharma PLC) since 2009 until May 2015. He served as a Director of Aciex Therapeutics Inc. (acquired by Nicox SA). He served as a Director at Transcept Pharmaceuticals, Inc. (merged with Paratek) since January 2009 and served as its Board Observer. He served as a Director of Paratek Pharmaceuticals, Inc. until October 30, 2014. He is Non-Executive Director at Qool Therapeutics. He is a Chartered Financial Analyst and is a member of the Chartered Financial Analyst Society of San Francisco. Mr. Nunn received an M.B.A. from the Stanford Graduate School of Business and an A.B. in Economics from Dartmouth College. He also holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco.
Positions
- Company NameZenas BioPharma, Inc.Stock CodeZBIOPositionIndependent DirectorColleagues
- LOLeon Oliver MoulderFounder, CEO & Chairman
- JLJoseph L. FarmerCOO, President, Principal Financial Officer & Principal Accounting Officer
- LVLisa von MoltkeHead of Research & Development and Chief Medical Officer
- HSHeinrich SchliekerChief Technical Officer
- HLHaley LakenChief Scientific Officer
- JJJohn Jacob OrloffIndependent Director
- PLPatricia L. AllenIndependent Director
- JPJames Patrick BoylanLead Independent Director
